Non-Invasive Liquid Biopsy Market Size to Reach USD 21.05 Billion in 2032
The Non-Invasive Liquid Biopsy Market size was USD 8.77 Billion in 2024 and is expected to register a revenue CAGR of 11.5% during the forecast period
March 11, 2025 – Increase in prevalence of cancer is a key driver driving non-invasive liquid biopsy market revenue growth. According to the American Cancer Society, prostate cancer in the US is projected to cause 313,780 new cases and 35,770 deaths by 2025. African American men and Caribbean men of African ancestry face a higher risk of prostate cancer than men of other races, with approximately one in every eight men developing the disease at some point in their lives. According to the Prostate Cancer UK, prostate cancer is the most common cancer in men, affecting over 50,000 men annually and resulting in over 12,000 deaths. One in every eight men will be diagnosed with prostate cancer at some point in their lives, and approximately 510,000 men are currently living with or have survived the disease.
On February 2024, DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, announced the availability of the company’s fragmentome-based research use only (RUO) cancer monitoring assay. The DELFI-Tumor Fraction (DELFI-TF) assay is a highly sensitive, inexpensive means of noninvasively measuring tumor burden and assessing treatment response and resistance in patients with advanced cancer
Several socioeconomic constraints impede the widespread implementation of liquid biopsy technology. Some commercially available diagnostics, particularly NGS, may be too expensive for clinical implementation and reimbursement in healthcare systems that rely on taxpayers or have limited resources. Furthermore, the technical requirements and experience in using these technologies may limit the application of liquid biopsy in clinical practice, especially in non-academic institutions with low economic and personnel resources.
Key Highlights:
- Extracellular vesicles (EV) segment is expected to register the fastest market share over the forecast period. Exosomes have significant promise as novel biomarkers in liquid biopsy, according to recent research, because they are abundant in body fluids and play a role in a variety of physiological and pathologic processes. Because of their lipid bilayers, exosomes are fundamentally durable and can circulate in physiological settings, including the hostile tumor microenvironment. The excellent biological stability enables the long-term storage of material for exosome isolation and detection.
- Non-cancer segment is expected to account for the fastest growth rate over the forecast period. Liquid biomarkers have also been found to play a role in the detection of the early stages of hypertensive and diabetic conditions. Studies in gastrointestinal (GI) oncology show that liquid biopsies can be used more effectively than tumor tissue samples, which can be limited and make genomic profiling difficult.
- North America accounted for largest market revenue share in the non-invasive liquid biopsy market in 2024 due to the increase in prevalence of cancer and technological advancements of non-invasive liquid biopsy instruments and kits. On June 2022, BillionToOne, Inc., a next-generation molecular diagnostics firm with a mission to make powerful and accurate testing available to everyone, has announced the launch of its first oncology liquid biopsy products, Northstar Select and Northstar Response. The products are now available for research use at select academic cancer institutions. Using BillionToOne’s patented molecular counting technique, or Quantitative Counting Templates (QCTs), the panel delivers an industry-leading limit of detection for identifying actionable mutations.
- Some major companies in the market report include QIAGEN, Exact Sciences Corporation, Thermo Fisher Scientific Inc., Freenome Holdings, Inc., F. Hoffmann-La Roche Ltd., Illumina, Inc., Epigenomics AG, Guardant Health, Myriad Genetics, Inc., Biocept, Inc., Lucence Health Inc., OraSure Technologies Inc., Norgen Biotek Corp, Zymo Research Corporation, and Oasis Diagnostics Corporation.
- On February 2025, Dxcover Limited, a clinical-stage diagnostics company pioneering multiomic spectrum analysis (MOSA-Dx) for early diagnosis of solid tumor malignancies, has announced the next critical stage of expansion, with significant finance secured to drive innovation and expand its commercial footprint. The investment round, worth USD 6.2 million, will be led by existing investors Eos Advisory, SIS Ventures, the University of Strathclyde, and Norcliffe Capital.
- On May 2023, Menarini Silicon Biosystems (MSB), a pioneer in liquid biopsy and single cell technologies, has announced a collaboration with Alivio Health. This new partnership provides Alivio Health clients and clinicians with privileged access to the vital information provided by the CELLSEARCH CTC tests, which allow for longitudinal monitoring of cancer patients at any moment during the disease’s progression.
Unlock the key to transforming your business strategy with our Non-Invasive Liquid Biopsy Market insights –
Navistrat Analytics has segmented non-invasive liquid biopsy market based on product and service, sample type, technology, circulating biomarker, application, and end-use:
- Product and Service Outlook (Revenue, USD Billion; 2022-2032)
- Instruments
- Software and Service
- Consumable Kits and Assays
- Sample Type Outlook (Revenue, USD Billion; 2022-2032)
- Urine
- Saliva
- Stool
- Blood
- Technology Outlook (Revenue, USD Billion; 2022-2032)
- Single Gene Analysis
- Multi-gene-parallel Analysis (NGS)
- Circulating Biomarker Outlook (Revenue, USD Billion; 2022-2032)
- Circulating Tumor Cells (CTCs)
- Circulating Tumor DNA
- Circulating Proteins
- Extracellular Vesicles
- Application Outlook (Revenue, USD Billion; 2022-2032)
- Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Leukemia
- Others
- Non-Cancer
- Non-Invasive Prenatal Testing
- Organ Transplantation
- Infectious Disease Testing
- Others
- Cancer
- End-Use Outlook (Revenue, USD Billion; 2022-2032)
-
- Hospitals and Laboratories
- Specialty Clinics
- Academic and Research Centers
- Others
-
- Regional Outlook (Revenue, USD Billion; 2022-2032)
-
- `North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Benelux
- Nordic Countries
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Oceania
- ASEAN Countries
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- GCC Countries
- South Africa
- Israel
- Turkey
- Rest of MEA
- `North America
-